<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">31722314</PMID><DateCompleted><Year>2019</Year><Month>11</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>01</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1881-6096</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>11</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Brain and nerve = Shinkei kenkyu no shinpo</Title><ISOAbbreviation>Brain Nerve</ISOAbbreviation></Journal><ArticleTitle>[Ropinirole Hydrochloride for ALS].</ArticleTitle><Pagination><StartPage>1279</StartPage><EndPage>1288</EndPage><MedlinePgn>1279-1288</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.11477/mf.1416201438</ELocationID><Abstract><AbstractText>Our laboratory previously established spinal motor neurons (MN) from induced-pluripotent stem cells (iPSCs) prepared from both sporadic and familial ALS patients, and successfully recapitulated disease-specific pathophysiological processes. We next searched for effective drugs capable of slowing the progression of ALS using a drug library of 1232 existing compounds and discovered that ropinirole hydrochloride prevented MN death. In December 2018, we started an investigator-initiated clinical trial testing ropinirole hydrochloride extended-release tablets in ALS patients. This is an on-going phase I/IIa randomized, double-blind, placebo-controlled, single-center, open-label continuation clinical trial (UMIN000034954). The primary aim is to assess the safety and tolerability of ropinirole hydrochloride in patients with ALS. We will also perform an efficacy evaluation using patient-derived iPSCs/MN. Major inclusion criteria were as follows: 1) 'clinically possible and laboratory-supported ALS', 'clinically probable ALS' or 'clinically definite ALS', according to the criteria for the diagnosis of ALS (El Escorial revised) and within 60 months after disease onset; 2) change in ALSFRS-R score of -2 to -5 points during the 12-week run-in period. Finally, 15 patients will be assigned to the active drug and 5 patients to the placebo. Our trial will be a touchstone trial for iPSC-based drug development strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Shinichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Stroke, Saitama medical university International medical center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morimoto</LastName><ForeName>Satoru</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fukushima</LastName><ForeName>Komei</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nakahara</LastName><ForeName>Jin</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Okano</LastName><ForeName>Hideyuki</ForeName><Initials>H</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Brain Nerve</MedlineTA><NlmUniqueID>101299709</NlmUniqueID><ISSNLinking>1881-6096</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007211">Indoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>030PYR8953</RegistryNumber><NameOfSubstance UI="C046649">ropinirole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="Y">Induced Pluripotent Stem Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="Y">cytology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31722314</ArticleId><ArticleId IdType="doi">10.11477/mf.1416201438</ArticleId><ArticleId IdType="pii">1416201438</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>